Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...

Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...

While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to ...

Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...

The stock's fall snapped a five-day winning streak.

This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.

Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its ...